Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).


NDAQ:IKT - Post by User

Inhibikase Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 6:16am
81 Views
Post# 36160034

Inhibikase Therapeutics, Inc. (NASDAQ:IKT): Advancing Innova

Inhibikase Therapeutics, Inc. (NASDAQ:IKT): Advancing Innovahttps://beyondspx.com/2024/08/01/inhibikase-therapeutics-inc-nasdaqikt-advancing-innovative-therapies-for-parkinsons-and-beyond/
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities